Metformin use and endometrial cancer survival

Gynecologic Oncology

Volumn 132, Issue 1, 2014, Pages 236-240

  Nevadunsky, Nicole S ^a   Van Arsdale, Anne ^a   Strickler, Howard D ^a   Moadel, Alyson ^a   Kaur, Gurpreet ^a   Frimer, Marina ^a   Conroy, Erin ^a   Goldberg, Gary L ^a   Einstein, Mark H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Adjuvant therapy; Endometrial cancer; Metformin; Non endometrioid; Retrospective cohort study

Indexed keywords

ANTINEOPLASTIC AGENT; METFORMIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; DRUG USE; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYSTERECTOMY; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; SURVIVAL RATE;

ADJUVANT THERAPY; EC; ENDOMETRIAL CANCER; METFORMIN; MMC; MONTEFIORE MEDICAL CENTER; NON-ENDOMETRIOID; OS; OVERALL SURVIVAL; RETROSPECTIVE COHORT STUDY;

AGED; COHORT STUDIES; DIABETES MELLITUS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84892735827     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.10.026     Document Type: Article

References (30)

1. A. Jemal, F. Bray, M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69
2. R. Siegal, E. Ward, O. Browley, and A. Jemal Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J Clin 61 2011 212
3. A. Fader, L. Arriba, H. Frasure, and V. Von Gruenigen Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship Gynecol Oncol 114 2009 121 127
4. M. Gunter, D. Hoover, H. Yu, S. Wassertheil-Smoller, J. Manson, and J. Li et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer Cancer Epidemiol Biomarkers Prev 17 4 2008 921 929
5. E. Friberg, N. Orsini, C. Mantzoros, and A. Wolk Diabetes mellitus and risk of endometrial cancer: a metanalysis Diabetologia 50 2007 1365
6. E. Giovanucci Nutrition, insulin, insulin-like growth factors and cancer Horm Metab Res 35 2003 694
7. American Diabetes Association Standards of medical care in diabetes - 2009 Diabetes Care 32 1 2009 S13 S61
8. R. Chlebowski, A. McTiernan, J. Wactawski-Wende, J. Manson, A. Aragaki, and T. Rohan Diabetes, metformin, and breast cancer in postmenopausal women J Clin Oncol 30 23 2012 2844 2852
9. H. Noto, K. Osame, T. Sasuazuki, and M. Noda Substantially increased risk of cancer in patients with diabetes mellitus: a systemic review and meta-analysis of epidemiologic evidence in Japan J Diabetes Complications 24 2010 345
10. M. Bodmer, C. Becker, C. Meier, S. Jick, and C. Meier Use of metformin and the risk of ovarian cancer: a case-control analysis Gynecol Oncol 123 2011 200 204
11. N. Sadeghi, J. Abbruzzese, S. Yeung, M. Hassan, and D. Li Metformin use is associated with better survival of diabetic patients with pancreatic cancer Clin Cancer Res 18 2012 2905 2912
12. L. Cantrell, C. Zhou, A. Mendivil, K. Malloy, P. Gehrig, and V. Bae-Jump Metformin is a potent inhibitor of endometrial cancer cell proliferation - implications for a novel treatment strategy Gynecol Oncol 116 1 2010 92 98
13. B. Tan, R. Adya, J. Chen, H. Lehnert, L. Saint Cassia, and H. Randeva Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells J Clin Endocrinol Metab 96 3 2012 808
14. L. Dong, Q. Zhou, Z. Zhang, Y. Zhu, T. Zuan, and Y. Feng Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression J Obstet Gynaecol Res 38 2012 1077 1085
15. R. Hanna, C. Zhou, K. Malloy, L. Sun, Y. Zhong, and P. Gehrig et al. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway Gynecol Oncol 125 2012 458 469
16. M. Owen, E. Doran, and A. Halestrap Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain Biochem J 348 2000 607 614
17. D. Hardie, F. Ross, and S. Hawley AMPK: a nutrient and energy sensor that maintains energy homeostasis Nat Rev Mol Cell Biol 13 2012 251 262
18. M. Pollak The insulin and insulin-like growth factor receptor family in neoplasia: an update Nat Rev Cancer 12 2012 159 169
19. S. Pecorelli, J. Benedet, W. Creasman, and J. Shepherd FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics Int J Gynecol Obstet 64 1 1999 5 10
20. F. Cirisano, S. Robboy, R. Dodge, R. Bently, H. Krigman, and I. Synan et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma Gynecol Oncol 74 1999 385 394
21. P. Goodwin, V. Stambolic, J. Lemieux, B. Chen, W. Parulekar, and K. Gelmon et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents Breast Cancer Res Treat 126 1 2011 215 220
22. N. Col, L. Ochs, V. Springmann, A. Aragaki, and R. Chlebowski Metformin and breast cancer risk: a meta-analysis and critical literature review Breast Cancer Res Treat 135 3 2012 639 646
23. P. Zhang, H. Li, X. Tan, L. Chen, and S. Wang Association of metformin use with cancer incidence and mortality: a meta-analysis Cancer Epidemiol 37 3 2012 207 218
24. I. Romero, A. McCormick, K. McEwen, S. Park, T. Karrison, and D. Yamada et al. Relationship of type II diabetes and metformin use to ovarian cancer, progression, survival and chemosensitivity Obstet Gynecol 119 1 2012 61 67
25. M. Lambe, M. Lambe, A. Wigertz, H. Garmo, G. Walldius, I. Gungner, and N. Hammar Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer Cancer Causes Control 22 8 2011 1163 1167
26. G. Landman, N. Kleefstra, K. van Hateren, K. Groenier, R. Gans, and H. Bilo Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC 16 Diabetes Care 33 2010 322 326
27. G. Huang, J. Brouwer-Visser, M. Ramirez, C. Kim, T. Hebert, and J. Lin et al. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer Clin Cancer Res 16 2010 2999 3010
28. D. Lehman, C. Lorenzo, J. Hernandez, and C. Wang Statin use as a moderator of metformin effect on risk for prostate cancer among type2 diabetic patients Diabetes Care 35 2012 1002 1007
29. S. Suissa, and L. Azoulay Metformin and the risk of cancer Diabetes Care 35 2012 2665 2673
30. W. Creasman, F. Odicino, P. Mausinneuve, M. Quinn, Y. Beller, and J. Benedet et al. Carcinoma of the corpus uteri Int J Gynecol Obstet 95 2006 S105 S143